Inotiv, Inc. Common Stock (NOTV) Debt to Equity (2009 - 2026)
Inotiv, Inc. Common Stock (NOTV) debt to equity from Sep 30, 2009 to Mar 31, 2026. The current Inotiv, Inc. Common Stock (NOTV) debt to equity is 532.32%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Inotiv, Inc. Common Stock (NOTV)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 295.61% | +28.14% |
| 2024 | 230.70% | +64.37% |
| 2023 | 140.35% | +49.35% |
| 2022 | 93.98% | -39.71% |
| 2021 | 155.87% | -52.27% |
| 2020 | 326.58% | +135.06% |
| 2019 | 138.94% | +59.79% |
| 2018 | 86.95% | +68.14% |
| 2017 | 51.71% | +5.40% |
| 2016 | 49.06% | +18.30% |
| 2015 | 41.47% | -24.49% |
| 2014 | 54.93% | -1.03% |
| 2013 | 55.50% | -20.37% |
| 2012 | 69.69% | N/A |
| 2012 | 69.69% | +51.45% |
| 2011 | 46.01% | N/A |
| 2011 | 46.01% | -41.06% |
| 2010 | 78.07% | N/A |
| 2010 | 0.00% | N/A |
| 2009 | 0.00% | N/A |
Comparison Inotiv, Inc. Common Stock (NOTV) debt to equity with competitors
Inotiv, Inc. Common Stock (NOTV) debt to equity is 532.32%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| CRL | Charles River Laboratories International Inc | 0.23% | -99.96% |
| OPK | Opko Health Inc | 0.29% | -99.94% |
| PRPO | Precipio Inc | 0.49% | -99.91% |
| CSTL | Castle Biosciences Inc | 2.18% | -99.59% |
| NTRA | Natera Inc | 4.53% | -99.15% |
| APDN | Applied Dna Sciences Inc | 4.60% | -99.14% |
| DGX | Quest Diagnostics Inc | 6.83% | -98.72% |
| PRPH | ProPhase Labs Inc | 7.54% | -98.58% |
| BLLN | Billiontoone Inc - Class A | 17.80% | -96.66% |
| IDXX | Idexx Laboratories Inc | 28.91% | -94.57% |
| ICLR | Icon Plc | 31.25% | -94.13% |
| WAT | Waters Corp | 31.75% | -94.04% |
| DHR | Danaher Corp | 34.91% | -93.44% |
| MYGN | Myriad Genetics Inc | 35.66% | -93.30% |
| WGS | GeneDx Holdings Corp - Class A | 38.06% | -92.85% |
| NEO | Neogenomics Inc | 40.86% | -92.32% |
| QGEN | Qiagen NV | 43.79% | -91.77% |
| RVTY | Revvity Inc | 44.66% | -91.61% |
| A | Agilent Technologies Inc | 47.11% | -91.15% |
| ADPT | Adaptive Biotechnologies Corp | 60.35% | -88.66% |
| LH | Laboratory Corp Of America Holdings | 72.57% | -86.37% |
| TMO | Thermo Fisher Scientific Inc | 88.65% | -83.35% |
| RDNT | Radnet Inc | 100.55% | -81.11% |
| XGN | Exagen Inc | 158.47% | -70.23% |
| IQV | IQVIA Holdings Inc | 254.51% | -52.19% |
| SHC | Sotera Health Company | 343.50% | -35.47% |
| BDSX | Biodesix Inc | 547.55% | +2.86% |